Randomized Trial: One Month of Rifapentine plus Isoniazid vs. 9 months of Isoniazid Alone for Preventing Tuberculosis in HIV-infected Patients with Latent Tuberculosis Infection
14 Mar, 2019 | 01:06h | UTCOne Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis – New England Journal of Medicine (free for a limited period)
Editorial: Ending Tuberculosis through Prevention (free)
Commentary: Ultrashort TB Therapy Found Just As Effective as 6 Month Course – MedicalResearch.com (free)
Related Commentary on Twitter
Treatment of latent #tuberculosis infection is an important control measure, especially in patients coinfected with #HIV. In this international phase 3 trial, 1 month of isoniazid plus rifapentine was noninferior to the standard 9 months of isoniazid in HIV-infected patients.
— NEJM (@NEJM) March 13, 2019